Time to Diagnosis and Treatment with Palliative Radiotherapy among Inuit Patients with Cancer from the Arctic Territory of Nunavut, Canada.


Journal

Clinical oncology (Royal College of Radiologists (Great Britain))
ISSN: 1433-2981
Titre abrégé: Clin Oncol (R Coll Radiol)
Pays: England
ID NLM: 9002902

Informations de publication

Date de publication:
01 2020
Historique:
received: 05 02 2019
revised: 13 05 2019
accepted: 28 05 2019
pubmed: 25 7 2019
medline: 4 9 2020
entrez: 24 7 2019
Statut: ppublish

Résumé

The cancer burden among Circumpolar Inuit is high. Palliative radiotherapy is a mainstay treatment for controlling symptoms of advanced cancers, but Inuit are required to travel far distances to access this service. Access to palliative radiotherapy and time away from home communities have not been explored among this population. We sought to describe the time intervals from symptom onset to the start of palliative radiotherapy among Canadian Inuit patients treated at The Ottawa Hospital (TOH). A retrospective review of Inuit patients from Nunavut treated with radiotherapy between 2005 and 2014 at TOH. Of a total of 152 radiotherapy patients, 88 (58%) were treated palliatively. Of these, 61 (70%) had stage IV disease at diagnosis and 63 (72%) had lung cancer. The median time from referral for specialist care to the patient's first flight to Ottawa was 4 days (range 0-97). The median length of treatment was 7 days (range 0-27), but patients spent a median of 64.5 days (range 14-633) in Ottawa. The median survival from the date of pathological diagnosis was 5.2 months. Most Inuit radiotherapy patients at TOH were treated palliatively. Patients were brought from Nunavut relatively quickly for specialist care, which is encouraging. However, patients spent over 2 months away from home, in the context of a median survival of less than 6 months. Opportunities for improvement include both provider and system-level changes, which may be applicable to other Circumpolar Inuit regions across Europe and North America.

Identifiants

pubmed: 31331816
pii: S0936-6555(19)30280-8
doi: 10.1016/j.clon.2019.07.001
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

60-67

Informations de copyright

Copyright © 2019 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Auteurs

J Chan (J)

Division of Radiation Oncology, The Ottawa Hospital and the University of Ottawa, Ottawa, Ontario, Canada; Department of Radiation Oncology, Amsterdam UMC - Vrije University Medical Center, Amsterdam, the Netherlands.

K Linden (K)

Radiation Medicine Program, The Ottawa Hospital, Ottawa, Ontario, Canada.

C McGrath (C)

Faculty of Science, University of Ottawa, Ottawa, Ontario, Canada.

J Renaud (J)

Radiation Medicine Program, The Ottawa Hospital, Ottawa, Ontario, Canada.

P Doering (P)

Regional Cancer Program, The Ottawa Hospital, Ottawa, Ontario, Canada.

S MacDonald (S)

Formerly with the Department of Health, Government of Nunavut, Iqaluit, Nunavut, Canada.

M Gaudet (M)

Division of Radiation Oncology, The Ottawa Hospital and the University of Ottawa, Ottawa, Ontario, Canada.

J R Pantarotto (JR)

Division of Radiation Oncology, The Ottawa Hospital and the University of Ottawa, Ottawa, Ontario, Canada.

T Asmis (T)

Division of Medical Oncology, The Ottawa Hospital and the University of Ottawa, Ontario, Canada.

B Slotman (B)

Department of Radiation Oncology, Amsterdam UMC - Vrije University Medical Center, Amsterdam, the Netherlands.

K Dennis (K)

Division of Radiation Oncology, The Ottawa Hospital and the University of Ottawa, Ottawa, Ontario, Canada. Electronic address: krdennis@toh.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH